Market Research Logo

Global HIV Drugs Market 2015-2019

Global HIV Drugs Market 2015-2019

About HIV

HIV is a type of retrovirus that causes infection in human beings. AIDS is a life-threatening disease caused by this virus. In this disease certain white blood cells (lymphocytes) are destroyed, resulting in the loss of the body's ability to protect itself against infections. The major route of transmission of HIV infection is unprotected sex, contaminated needle, breast milk, and infected blood. HIV attacks the body's white blood cells, specifically a subset called CD4 or helper T cells. The anti-retroviral therapy is used to treat the patient and help the immune system fight the infection. This is mainly used to keep the level of the HIV low in the body.

Technavio's analysts forecast the global HIV drugs market to grow at a CAGR of 4.52% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global HIV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic and branded drugs and the expected launch of drug candidates used in the treatment of HIV infection.

Based on the class of drugs, the market is segmented as follows:

  • Multi-class combination products
  • Nucleoside reverse transcriptase inhibitors
  • Non-nucleoside reverse transcriptase inhibitors
  • Protease inhibitors
  • Fusion inhibitors
  • Entry inhibitors - CCR5 co-receptor antagonist
  • HIV integrase strand transfer inhibitors
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

Technavio's report, Global HIV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
  • Americas
  • APAC
  • EMEA
Key vendors
  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
Other prominent vendors
  • AbbVie
  • AstraZeneca
  • Boehringer Ingelheim
  • Cipla
  • Daiichi Sankyo
  • Emcure
  • F. Hoffmann-La Roche
  • Hetero Drugs
  • Mylan
  • Pfizer
  • Shionogi
  • Teva Pharmaceutical Industries
Market driver
  • Inflow of funds
  • For a full, detailed list, view our report
Market challenge
  • Patent expiries
  • For a full, detailed list, view our report
Market trend
  • Increasing public awareness
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global HIV Drugs Market 2015-2019

Technavio recognizes the following companies as the key players in the Global HIV Drugs Market: Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, and Merck.

Other Prominent Vendors in the market are: AbbVie, AstraZeneca, Boehringer Ingelheim, Cipla, Daiichi Sankyo, Emcure, F. Hoffmann-La Roche, Hetero Drugs, Mylan, Pfizer, Shionogi, and Teva Pharmaceutical Industries.

Commenting on the report, an analyst from Technavio’s team said: “Strategic alliances formed between companies, in terms of licensing and collaboration, is a key market trend that is helping co-development and commercialization of drugs in different regions.”

According to the report, unmet medical needs in the market present significant growth opportunities for vendors.

Further, the report states that adverse effects such as hepatotoxicity, hyperglycemia, hyperlipidemia, lactic acidosis, lipodystrophy, osteonecrosis, osteopenia, osteoporosis, and skin rash presents a significant challenge to this market.

Companies Mentioned

Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, AbbVie, AstraZeneca, Boehringer Ingelheim, Cipla, Daiichi Sankyo, Emcure, F. Hoffmann-La Roche, Hetero Drugs, Mylan, Pfizer, Shionogi, Teva Pharmaceutical Industries.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global HIV drugs market 2014-2019 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Table Global HIV drugs market segmentation by drug class 2014
    • Table Global HIV drugs market segmentation by drug class 2014-2019 ($ millions)
  • Global multi-class combination products market
    • Table Global multi-class combination products market 2014-2019 ($ millions)
  • Global nucleoside reverse transcriptase inhibitors market
    • Table Global nucleoside reverse transcriptase inhibitors market 2014-2019 ($ millions)
  • Global non-nucleoside reverse transcriptase inhibitors market
    • Table Global non-nucleoside reverse transcriptase inhibitors market 2014-2019 ($ millions)
  • Global protease inhibitors market
    • Table Global protease inhibitors market 2014-2019 ($ millions)
  • Global fusion inhibitors market
    • Table Global fusion inhibitors market 2014-2019 ($ millions)
  • Global entry inhibitors - CCR5 co-receptor antagonist market
    • Table Global entry inhibitors - CCR5 co-receptor antagonist market 2014-2019 ($ millions)
  • Global HIV integrase strand transfer inhibitors market
    • Table Global HIV integrase strand transfer inhibitors market 2014-2019 ($ millions)
  • Geographical segmentation
    • Global HIV drugs market segmentation by geography
      • Table Global HIV drugs market segmentation by geography 2014
      • Table Global HIV drugs market segmentation by geography 2014-2019 ($ millions)
      • Table HIV drugs market in Americas 2014-2019 ($ millions)
      • Table HIV drugs market in EMEA 2014-2019 ($ millions)
      • Table HIV drugs market in APAC 2014-2019 ($ millions)
  • Market drivers
    • Increased funding
      • Table Assistance from donor governments for HIV treatment 2013
    • Rise in patient population
      • Table Global HIV statistics 2014
    • Unmet medical needs
    • Initiatives by governments
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Expiry of patents
    • Associated social stigma
    • Side effects of drugs
    • Complications in disease diagnosis
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Rise in public awareness
    • Strategic alliances
    • Novel approaches
  • US Government: Funding for HIV
    • Table Funding by the US government for HIV 2010-2016 ($ billions)
    • Table Funding by the US government for domestic treatment and care of HIV 2010-2016 ($ billions)
  • Vendor landscape
    • Competitive scenario
    • Market share analysis
      • Table Bristol-Myers Squibb: Revenue of Reyataz 2012-2014 ($ billions)
      • Table Bristol-Myers Squibb: Revenue of Sustiva 2012-2014 ($ billions)
      • Table Gilead Sciences: Revenue of Stribild 2012-2014 ($ millions)
      • Table Gilead Sciences: Revenue of Truvada 2012-2014 ($ billions)
      • Table Gilead Sciences: Revenue of Emtriva 2012 and 2013 ($ millions)
      • Table Gilead Sciences: Revenue of Atripla 2012-2014 ($ billions)
      • Table Gilead Sciences: Revenue of Complera/Eviplera 2012-2014 ($ millions)
      • Table Gilead Sciences: Revenue of Viread 2012-2014 ($ millions)
      • Table GlaxoSmithKline: Revenue of Combivir 2012-2014 ($ millions)
      • Table GlaxoSmithKline: Revenue of Trizivir 2012-2014 ($ millions)
      • Table GlaxoSmithKline: Revenue of Agenerase and Lexiva 2012-2014 ($ millions)
      • Table GlaxoSmithKline: Revenue of Tivicay 2013-2014 ($ millions)
      • Table Johnson & Johnson: Revenue of Edurant 2012-2014 ($ millions)
      • Table Johnson & Johnson: Revenue of Prezista 2012-2014 ($ billions)
      • Table Merck: Revenue of Isentress 2012-2014 ($ billions)
    • Other prominent vendors
  • Key vendor analysis
    • Bristol-Myers Squibb
    • Gilead Sciences
    • GlaxoSmithKline
    • Johnson & Johnson
    • Merck
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report